Inflammation and hypertension: The interplay of interleukin-6, dietary sodium, and the renin-angiotensin system in humans

American Journal of Hypertension

Volumn 24, Issue 10, 2011, Pages 1143-1148

  Chamarthi, Bindu ^a   Williams, Gordon H ^a   Ricchiuti, Vincent ^a   Srikumar, Nadarajah ^b   Hopkins, Paul N ^c   Luther, James M ^d   Jeunemaitre, Xavier ^e,f,g   Thomas, Abraham ^h  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Bryan LGH Heart Institute   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^g INSERM   (France)

^h HENRY FORD HOSPITAL   (United States)

Author keywords

angiotensin; blood pressure; CRP; hypertension; IL 6; inflammation; sodium

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN II; C REACTIVE PROTEIN; INTERLEUKIN 6; RENIN; SODIUM;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; INFLAMMATION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM INTAKE; SODIUM RESTRICTION;

ADULT; ANGIOTENSIN II; C-REACTIVE PROTEIN; DIET, SODIUM-RESTRICTED; FEMALE; HUMANS; HYPERTENSION; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 80052964672     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1038/ajh.2011.113     Document Type: Article

References (40)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340:115-126.
2. Ridker PM. Intrinsic fibrinolytic capacity and systemic inflammation: novel risk factors for arterial thrombotic disease. Haemostasis 1997; 27 Suppl 1:2-11. (Pubitemid 27521230)
3. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336:973-979. (Pubitemid 27152782)
4. Sinisalo J, Paronen J, Mattila KJ, Syrjälä M, Alfthan G, Palosuo T, Nieminen MS, Vaarala O. Relation of inflammation to vascular function in patients with coronary heart disease. Atherosclerosis 2000; 149:403-411. (Pubitemid 30145551)
5. Bautista LE, López-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001; 19:857-861. (Pubitemid 32436948)
6. Bautista LE. Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. J Hum Hypertens 2003; 17: 223-230. (Pubitemid 36592013)
7. Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens 2005; 19:149-154. (Pubitemid 40220638)
8. Bautista LE, Atwood JE, O'Malley PG, Taylor AJ. Association between C-reactive protein and hypertension in healthy middle-aged men and women. Coron Artery Dis 2004; 15:331-336. (Pubitemid 39299248)
9. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension 2001; 38:399-403. (Pubitemid 34225673)
10. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290:2945-2951. (Pubitemid 37505526)
11. Lakoski SG, Cushman M, Palmas W, Blumenthal R, D'Agostino RB Jr, Herrington DM. The relationship between blood pressure and C-reactive protein in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol 2005; 46:1869-1874. (Pubitemid 41579810)
12. Lakoski SG, Herrington DM, Siscovick DM, Hulley SB. C-reactive protein concentration and incident hypertension in young adults: the CARDIA study. Arch Intern Med 2006; 166:345-349. (Pubitemid 43244323)
13. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101:1767-1772. (Pubitemid 30213096)
14. Biasucci LM, Liuzzo G, Fantuzzi G, Caligiuri G, Rebuzzi AG, Ginnetti F, Dinarello CA, Maseri A. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999; 99:2079-2084. (Pubitemid 29196789)
15. Koukkunen H, Penttilä K, Kemppainen A, Halinen M, Penttila I, Rantanen T, Pyörälä K. C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris. Ann Med 2001; 33:37-47. (Pubitemid 32238755)
16. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA 2001; 286:2107-2113. (Pubitemid 34041595)
17. Tan J, Hua Q, Li J, Fan Z. Prognostic value of interleukin-6 during a 3-year follow-up in patients with acute ST-segment elevation myocardial infarction. Heart Vessels 2009; 24:329-334.
18. Funakoshi Y, Ichiki T, Ito K, Takeshita A. Induction of interleukin-6 expression by angiotensin II in rat vascular smooth muscle cells. Hypertension 1999; 34: 118-125. (Pubitemid 29325729)
19. Lee DL, Sturgis LC, Labazi H, Osborne JB Jr, Fleming C, Pollock JS, Manhiani M, Imig JD, Brands MW. Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. Am J Physiol Heart Circ Physiol 2006; 290:H935-H940.
20. Brands MW, Banes-Berceli AK, Inscho EW, Al-Azawi H, Allen AJ, Labazi H. Interleukin 6 knockout prevents angiotensin II hypertension: role of renal vasoconstriction and janus kinase 2/signal transducer and activator of transcription 3 activation. Hypertension 2010; 56:879-884.
21. Ridker PM, Danielson E, Rifai N, Glynn RJ; Val-MARC Investigators. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension 2006; 48:73-79.
22. Dandona P, Kumar V, Aljada A, Ghanim H, Syed T, Hofmayer D, Mohanty P, Tripathy D, Garg R. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab 2003; 88:4496-4501. (Pubitemid 37153762)
23. Fliser D, Buchholz K, Haller H; EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110:1103-1107. (Pubitemid 39319009)
24. Luther JM, Gainer JV, Murphey LJ, Yu C, Vaughan DE, Morrow JD, Brown NJ. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension 2006; 48:1050-1057. (Pubitemid 44772707)
25. Grant FD, Romero JR, Jeunemaitre X, Hunt SC, Hopkins PN, Hollenberg NH, Williams GH. Low-renin hypertension, altered sodium homeostasis, and an alphaadducin polymorphism. Hypertension 2002; 39:191-196. (Pubitemid 34165213)
26. Kosachunhanun N, Hunt SC, Hopkins PN, Williams RR, Jeunemaitre X, Corvol P, Ferri C, Mortensen RM, Hollenberg NK, Williams GH. Genetic determinants of nonmodulating hypertension. Hypertension 2003; 42:901-908. (Pubitemid 37413728)
27. Chamarthi B, Kolatkar NS, Hunt SC, Williams JS, Seely EW, Brown NJ, Murphey LJ, Jeunemaitre X, Williams GH. Urinary free cortisol: an intermediate phenotype and a potential genetic marker for a salt-resistant subset of essential hypertension. J Clin Endocrinol Metab 2007; 92:1340-1346. (Pubitemid 46556407)
28. Hopkins PN, Lifton RP, Hollenberg NK, Jeunemaitre X, Hallouin MC, Skuppin J, Williams CS, Dluhy RG, Lalouel JM, Williams RR, Williams GH. Blunted renal vascular response to angiotensin II is associated with a common variant of the angiotensinogen gene and obesity. J Hypertens 1996; 14:199-207. (Pubitemid 26121862)
29. Underwood RH, Williams GH. The simultaneous measurement of aldosterone, cortisol, and corticosterone in human peripheral plasma by displacement analysis. J Lab Clin Med 1972; 79:848-862.
30. Emanuel RL, Cain JP, Williams GH. Double antibody radioimmunoassay of renin activity and angiotensin II in human peripheral plasma. J Lab Clin Med 1973; 81:632-640.
31. Schuett H, Luchtefeld M, Grothusen C, Grote K, Schieffer B. How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost 2009; 102:215-222.
32. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103:1813-1818. (Pubitemid 32291421)
33. Brasier AR, Recinos A 3rd, Eledrisi MS. Vascular inflammation and the reninangiotensin system. Arterioscler Thromb Vasc Biol 2002; 22:1257-1266.
34. Kranzhöfer R, Schmidt J, Pfeiffer CA, Hagl S, Libby P, Kübler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999; 19:1623-1629. (Pubitemid 29323820)
35. Kranzhöfer R, Browatzki M, Schmidt J, Kübler W. Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes. Biochem Biophys Res Commun 1999; 257:826-828. (Pubitemid 29301525)
36. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol, Cell Physiol 2007; 292:C82-C97. (Pubitemid 46127306)
37. Pastore L, Tessitore A, Martinotti S, Toniato E, Alesse E, Bravi MC, Ferri C, Desideri G, Gulino A, Santucci A. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 1999; 100:1646-1652. (Pubitemid 29477275)
38. Sturgis LC, Cannon JG, Schreihofer DA, Brands MW. The role of aldosterone in mediating the dependence of angiotensin hypertension on IL-6. Am J Physiol Regul Integr Comp Physiol 2009; 297:R1742-R1748.
39. Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995; 269:E657-E662.
40. Martinez DV, Rocha R, Matsumura M, Oestreicher E, Ochoa-Maya M, Roubsanthisuk W, Williams GH, Adler GK. Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading. Hypertension 2002; 39:614-618. (Pubitemid 34165193)